ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that preclinical data related to camidanlumab tesirine (Cami, formerly ADCT-301) has been published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for Immunotherapy of Cancer, in a paper titled, "CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.”
The study evaluated the antitumor activity of a pyrrolobenzodiazepine (PBD) dimer-based, CD25-targeted ADC, either alone or in combination with a checkpoint inhibitor, in CD25-negative syngeneic colon cancer models that exhibit tumor infiltration of CD25-expressing regulatory T cells (Tregs). Data demonstrated that single low doses of the CD25-targeted ADC resulted in potent and durable antitumor activity against established CD25-negative solid tumors with infiltrating Tregs, both as a monotherapy and in combination with an anti-PD1 checkpoint inhibitor.
Patrick van Berkel, Ph.D., Senior Vice President of Research and Development at ADC Therapeutics, said, "CD25 is expressed on Tregs that infiltrate the local tumor environment. We were pleased to see that our CD25-targeted ADC depleted CD25-expressing Tregs and not only showed strong anti-tumor activity as a monotherapy in preclinical models, but it also enhanced the activity of anti-PD1 treatment in these models. This study provides proof of concept for a new application of ADCs as immunotherapeutic agents and supports the continued evaluation of Cami in our ongoing Phase 1b clinical trial in patients with selected advanced solid tumors. We look forward to advancing the exploration of Cami as a novel immune-oncology approach for the treatment of solid tumors.”
For information about the company’s Phase 1b clinical trial of Cami in solid tumors, visit www.clinicaltrials.gov (identifier NCT03621982).
About Camidanlumab Tesirine (Cami)
Camidanlumab tesirine (Cami, formerly ADCT-301) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead killing the cell. This applies to CD25-expressing tumor cells, and also to CD25-expressing Tregs. The intra-tumoral release of its PBD warhead may also cause bystander killing of neighboring tumor cells and PBDs have also been shown to induce immunogenic cell death. All these properties of Cami may enhance immune-mediated anti-tumor activity. Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma (HL), as well as in a Phase 1a/1b clinical trial in patients with relapsed or refractory HL and non-Hodgkin lymphoma and a Phase 1b clinical trial in solid tumors.
About ADC Therapeutics
ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase 2 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.
Loncastuximab tesirine (Lonca, formerly ADCT-402), the Company’s lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR), which exceeded the target primary endpoint. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company’s second lead product candidate, is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) after having shown an 86.5% ORR in HL patients in a Phase 1 clinical trial. The Company is also evaluating Cami as a novel immuno-oncology approach for the treatment of various advanced solid tumors.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005550/en/
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- There's a new breed of buy now, pay later (BNPL) services being offered to online shoppers. You may have noticed one of these installment plan options while shopping online at your favorite retailer. These plans allow purchases to be paid off in multiple payments over time rather than all at once. They're similar to layaway, except that your products are shipped right away. What follows is what you need to know about buy now, pay later services and credit, from myFICO.
For more loan and credit education, visit myFICO's blog at https://www.myfico.com/credit-education/blog.
How Buy Now, Pay Later Services Work
Some BNPL services are offered with no fees or interest and sometimes no upfront payment, which can be attractive even for shoppers who have a credit card with available credit. Depending on the purchase amount, you may be presented with multiple payment options with different monthly payment amounts and interest rates. Choose the one that fits your budget, then provide your payment information.
For repayment, the service may link directly to your banking account, making it easier to pay off the balance and eliminate late payments as long as the account is open and funds are available.
Shoppers are embracing the opportunity to buy now and pay later. According to a survey from The Ascent by Motley Fool, more than a third of U.S. consumers have used a BNPL service. While most people say they have used the services to avoid paying credit card interest or buy something not in their budget, only ~22% say they understand all the service's terms and conditions.
The Impact on Your Credit
Remember that even if there's no credit check for a BNPL service, your credit could still be impacted. For example, missed payments could affect your FICO® Score, according to Janet Alvarez, Credit Card & Personal Finance Expert at The Ascent by The Motley Fool. You could also face penalty interest rates or fees on top of negative marks on your credit report.
Most services require you to provide your credit or debit card information, which typically help you avoid missed payments. However, you could default if your payment is declined or returned by the bank, for example, if you don't have sufficient funds or your account is closed. The provider might also consider you to be in default if you file for bankruptcy while you have an outstanding installment plan, you provide false or inaccurate information, or you otherwise violate the terms of the installment agreement.
Some services may check your credit to determine eligibility. With Affirm and Klarna, these aren't hard credit checks that affect your credit.
PayPal Credit may be offered at checkout, but you're actually signing up for a reusable line of credit, which is more like a credit card than a BNPL service. Some purchases made with PayPal Credit qualify for six months with no interest, and monthly payments are reported to the credit bureaus, whether late or on-time.
Tips for Borrowing Responsibly
If you're using a credit card as the payment method for the BNPL purchase, make sure you pay that balance in full and on-time each month. Otherwise, carrying a balance will lead to interest, and late payments will incur a fee and potentially damage your FICO® Score
Like other inaccurate information, you're allowed to file a dispute with the credit bureaus if you believe information about a BNPL service is inaccurate. Accurate negative information can remain on your credit report for up to seven years and factor into your FICO® Score.
Of course, when you're considering BNPL services for purchases, you should factor in your ability to pay. Smaller payments could tempt you into spending more than you actually can afford. While the payments may be more affordable, keep in mind any major expenses you have coming up that could impact your payments.
myFICO makes it easy to understand your credit with FICO® Scores, credit reports and alerts from all 3 bureaus. myFICO is the consumer division of FICO– get your FICO Scores from the people that make the FICO Scores. For more information, visit https://www.myfico.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/how-buy-now-pay-later-services-affect-your-credit-301160035.html
Apple and Google have both banned Parler from their app stores.
OLIVIER DOULIERY/AFP via Getty ImagesApple has banned the social media app Parler from the App Store for failing to remove content that promotes violence.
"Parler has not taken adequate measures to address the proliferation of these threats to people's safety," Apple said in a statement.
The move comes one day after Google banned the fast-growing app from its store for similar reasons.
Visit Business Insider's homepage for more stories.
Apple has banned the fast-growing social media app Parler from its App Store for failing to remove content that promoted violence, The New York Times reported.
"We have always supported diverse points of view being represented on the App Store, but there is no place on our platform for threats of violence and illegal activity," Apple said in a statement provided to The Times. "Parler has not taken adequate measures to address the proliferation of these threats to people's safety."
Parler became popular in recent months among supporters of President Donald Trump and members of the far right due to its lack of moderation. The platform was used by some to plan the deadly siege on the US Capitol this week.
Apple's ban comes one day after Google banned the app from its Play Store, citing similar reasons, Insider's Tyler Sonnemaker reported.
"We're aware of continued posting in the Parler app that seeks to incite ongoing violence in the US. We recognize that there can be reasonable debate about content policies and that it can be difficult for apps to immediately remove all violative content, but for us to distribute an app through Google Play, we do require that apps implement robust moderation for egregious content," a Google spokesperson told Insider.
Both bans make Parler unavailable in the app stores run by Apple and Google. The app may still be able to be accessed through third-party app stores or mobile browsers.